Perspective Therapeutics, Inc.

CATX Healthcare Medical Devices

Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024.

Revenue
−72.1%
EPS
+24.1%
Free cash flow
−66.1%
Total debt
−3.57%

Quarter to June 2026, against a year earlier

0.84 0.05 +6.33%
Market cap
$90.0M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
3/9
Altman Z
−0.59
Beneish M
0.59
Dividend safety
n/a
Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
4 4 6 3 4 1 — — — 3
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
P/S ratio
72.22 40.70 37.58 38.83 82.43 4.07 — 74.84 141.35 229.62
Altman Z-Score
3.68 (10.36) (3.36) (6.24) 15.80 7.08 — (0.69) 1.37 (0.59)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(11.16) (35.41) (24.04) (30.66) 25.06 20.50 — (4.33) 6.14 (0.38)
P/Operating CF
(283.47) (166.47) (279.06) (443.23) (741.19) (15.18) — (11.91) (7.72) (8.23)
Beneish M-Score
(3.45) (3.25) (2.65) (1.41) (2.56) (1.76) — — (4.35) 0.59
P/B ratio
32.43 47.92 35.79 65.68 12.29 0.72 — 1.43 0.71 0.98
EV/Sales
70.98 40.12 36.85 38.66 76.13 (1.09) — 69.57 (13.60) 67.67
EV/EBITDA
0.00 0.00 0.00 0.00 20,140.72 3.56 — 0.00 0.30 0.00
EV/FCF
(35.54) (25.32) (32.14) (61.87) (170.53) 1.47 — (2.63) 0.27 (0.63)
Current Ratio
9.30 2.97 6.53 3.50 37.37 26.18 17.07 1.07 12.68 5.17
Net Debt/EBITDA
0.96 0.52 1.05 0.50 19.60 9.06 0.00 0.19 3.46 1.27
Debt/Equity
0.00 0.00 0.00 0.13 0.01 0.00 0.00 0.02 0.01 0.01
ROE
(45.72%) (85.86%) (81.12%) (51.59%) (9.27%) (11.30%) 0.00% (71.65%) (43.34%) (41.44%)
ROA
(40.65%) (68.05%) (61.09%) (38.15%) (8.57%) (10.78%) 0.00% (59.63%) (36.12%) (33.92%)
ROIC
(84.41%) (262.03%) (139.50%) (52.99%) (52.50%) (71.09%) 0.00% (37.84%) (86.89%) (111.14%)
Return on Tangible Assets
(60.29%) (136.35%) (66.06%) (61.00%) (5.03%) (12.32%) 0.00% (689.11%) (29.34%) (52.53%)
Average Days of Receivables
55.66 73.46 57.59 77.07 73.09 54.37 0.00 296.53 29.12 2.48
Earnings Yield
(13.28%) (19.22%) (15.12%) (5.76%) (3.39%) (16.32%) — (43.78%) (37.08%) (50.80%)
Free Cash Flow Yield
(2.77%) (3.89%) (3.05%) (1.61%) (0.54%) (18.18%) — (35.39%) (35.22%) (46.92%)
Free Cash Flow per Share
(1.14) (1.10) (0.81) (0.58) (0.31) (0.56) — (1.42) (1.12) (1.29)
Book value per Share
1.93 0.91 1.15 0.85 6.49 4.32 0.00 2.81 4.51 2.80
Free Cash Flow
(6.25) (6.05) (5.46) (3.91) (3.22) (7.98) — (37.98) (72.37) (95.23)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 1.59 — 0.00 0.22 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026